These include: Orlistat : A lipase inhibitor that reduces fat absorption, with a different mechanism and side effect profile than appetite suppressants Naltrexone-bupropion : A combination medication affecting reward pathways and appetite regulation Phentermine-topiramate ER (Qsymia) : An FDA-approved combination that has been studied more extensively than phentermine-semaglutide and is approved for long-term use Tirzepatide (Zepbound) : A dual GIP/GLP-1 receptor agonist that has demonstrated greater weight loss than semaglutide in head-to-head clinical trials (SURMOUNT-5) Intensive lifestyle interventions remain foundational to successful weight management
[DOI] [PubMed] [Google Scholar] 50.Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al
Days five through seven (the taper) As blood levels decline toward the end of the weekly cycle, some people notice a gradual return of appetite
Can J Diabetes 2022;46(1): 10e5
This should never be painful
Goia-Nishide K, Coregliano-Ring L, Rangel B